6 results
8-K
EX-99.1
RVMD
Revolution Medicines Inc
8 May 23
Revolution Medicines Reports First Quarter 2023 Financial Results and Update on Corporate Progress
4:04pm
at Genentech. During her tenure she worked across the company’s oncology/hematology portfolio, where she served as lifecycle leader of cancer
8-K
EX-99.1
RVMD
Revolution Medicines Inc
9 Aug 22
Revolution Medicines Reports Second Quarter 2022 Financial Results and Update on Corporate Progress
12:00am
oncology markets. During his previous tenure with Genentech, he led lifecycle management of Tecentriq® (atezolizumab) in lung cancer and helped lead more
DEFA14A
mw3v23h zz46cnhtg
3 May 21
Additional proxy soliciting materials
7:15am
- Prev
- 1
- Next